

state mandates for health education,  
23:5-7, 23:13, 23:15-16, 23:18  
state smoking laws, 21:27-28

#### **LEUKEMIA**

(See also **NEOPLASMS**)

benzene and, 14:51

#### **LEUKOCYTES**

cell count in cigar and pipe smokers,  
12:81

cell count in ex-smokers, 12:81

cell count in smokers vs. nonsmokers,  
12:79-82

chemotaxis in smokers vs. nonsmok-  
ers, 12:82

effect of inhalation and smoking lev-  
els on cell count, 79-82

granular, levels in smokers, 10:20

#### **LEUKOPLAKIA**

(See also **MOUTH NEOPLASMS**)

betel chewing and, 5:41

bidi smoking and, 5:41

snuff in etiology of, 13:40

tobacco chewing and, 5:41

tobacco chewing in etiology of,  
13:40-41

#### **LIFE EXPECTANCY**

(See also **MORTALITY**)

definition, 2:11

effect of smoking levels in the Unit-  
ed States, 2:12

#### **LIFE SKILLS TRAINING**

antismoking education component,  
20:11

#### **LIP NEOPLASMS**

(See also **MOUTH NEOPLASMS**)

alcohol consumption and smoking  
and, 5:41

pipe smoking and, 1:27

pipe smoking in etiology of, 13:21

relative risk in cigarette vs. cigar vs.  
pipe smokers, 13:22

#### **LIPIDS**

effect of smoking on metabolism,  
12:65

#### **LIVER**

function, effect of aromatic hydro-  
carbons, 12:7-8

organ weight in smokers vs. non-  
smokers, 12:9

#### **LOBELINE**

nicotine substitute, 19:16-17

#### **LOCUS OF CONTROL**

academic achievement and, 20:22

cessation of smoking and, 18:18  
maintenance of smoking and, 18:9

#### **Low-tar cigarettes**

See **CIGARETTES, LOW-TAR**

#### **Lung diseases**

See **BRONCHOPULMONARY DIS-  
EASES; BYSSINOSIS; CHRONIC  
OBSTRUCTIVE LUNG DISEASES;  
RESPIRATORY TRACT DIS-  
EASES**

#### **LUNG FUNCTION**

(See also **RESPIRATORY FUNC-  
TION TESTS**)

effect of carbon monoxide exposure,  
11:27-28

effect of cessation of smoking, 6:22-  
23

effect of cigar smoking, 13:34-35,  
13:38

effect of nicotine, 14:90

effect of passive smoking in asth-  
matic patients, 10:22

effect of pipe smoking, 13:34-35,  
13:38

effect of smoking, 6:22, 14:90

effect of smoking, summary of find-  
ings, 1:18

effect of smoking levels, 6:22

sex ratio, 6:21-22

in smokers vs. nonsmokers, 6:21

in smokers vs. nonsmokers vs. ex-  
smokers, 6:23

smoking in chlorine workers and,  
7:10

smoking in coal miners and, 7:9

smoking in cotton workers and, 7:9

in white, black and oriental smoking  
and nonsmoking men and wom-  
en, 6:21

#### **LUNG NEOPLASMS**

(See also **BRONCHIAL NEO-**

**PLASMS; RESPIRATORY TRACT  
NEOPLASMS**)

air pollution in etiology of, 5:25-27

animal models, 5:29-31

aryl hydrocarbon hydroxylase induci-  
bility and, 5:57

asbestos and smoking in etiology of,  
5:28

carcinoembryonic antigen test in di-  
agnosis of, 12:61

chloromethyl ethers and smoking in  
etiology of, 5:29

in chloromethyl ether workers, 7:16  
 cigar and pipe smoking and, summary of findings, 1:28  
 cigar smoking in etiology of, 13:28  
 effect of age began smoking on mortality ratio, 13:14  
 effect of cessation of smoking on risk and mortality ratios, 5:24-26  
 effect of filtered vs. unfiltered cigarettes on risk, 5:16, 5:18-19  
 effect of inhalation on mortality ratio, 5:14-15  
 effect of low tar and nicotine cigarettes on mortality ratio, 5:15-17  
 effect of smoking levels on mortality ratio, 5:13  
 effect of smoking levels on risk, 5:12-13, 5:16, 5:18-19  
 effect of smoking on histologic type, 5:23-24  
 effect of smoking on mortality rates, 5:9-11  
 heredity and, 5:23  
 histologic types, 5:23-24  
 induced by benzo(a)pyrene in hamsters, 5:30  
 induced by nitrosamines in animals, 5:30  
 mortality in asbestos workers, 7:11-12  
 mortality rates in cigar vs. pipe smokers, 5:23  
 mortality rates in women, 5:16-18, 5:20-  
 mortality ratio in cigar vs. cigarette vs. pipe smokers, 13:26  
 mortality rate trends in Great Britain and the United States, 5:10-11  
 mortality ratio in smokers vs. nonsmokers, 5:11-12  
 nickel and smoking in etiology of, 5:28  
 occupational exposures and smoking in etiology of, 5:27-29, 7:17  
 relative risk in cigar vs. cigarette vs. pipe smokers, 13:29-30  
 role of pulmonary alveolar macrophages, 5:31  
 smoking and, summary of findings, 1:16  
 smoking and occupational risk in whites and nonwhites, 7:17

smoking in asbestos workers and, 7:11-13  
 smoking in etiology of, historical perspective, 5:9  
 smoking in uranium miners and, 7:14  
 in smoking vs. nonsmoking twins, 5:23  
 uranium and smoking in etiology of, 5:28  
 in urban vs. rural areas, 5:25-27

## **LUNGS**

(*See also* **RESPIRATORY SYSTEM**)

air pollution and pathology in smokers vs. nonsmokers, 6:36  
 effect of cigar smoking, 13:35  
 effect of pipe smoking, 13:35  
 effect of smoke inhalation in dogs, 14:76  
 effect of smoke inhalation in monkeys, 14:76  
 effect of smoking, 6:18  
 effect of smoking, summary of findings, 1:18-19  
 effect of smoking levels on pathology, 6:24-27  
 effect of smoking on pathogenesis, 6:25-26  
 enzyme induction of emphysema, 6:28  
 nicotine absorption, 14:85  
 organ weight in smokers vs. nonsmokers, 12:9

## **LYMPHOCYTES**

B and T, in smokers vs. nonsmokers, 6:31  
 effect of smoking, 10:19  
 effect of tobacco smoke in mice, 10:19  
 effect of tobacco smoke on immune function, 10:17

## **MACROPHAGES, ALVEOLAR**

(*See also* **PHAGOCYTOSIS**)

in bronchial fluid of smokers, 6:28  
 count in smokers vs. nonsmokers, 6:29  
 effect of cigarette smoke, 6:29-30  
 effect of cigarette smoke on phagocytic activity, 10:17  
 effect of tobacco smoke, 10:15-16  
 effect of tobacco smoke on count and ultrastructure, 10:16

effect of smoke inhalation in dogs, 14:76  
 effect of smoke inhalation in monkeys, 14:76  
 elastase release in smokers vs. nonsmokers, 6:30  
 in lung neoplasm etiology, 5:31  
 protease activity in smokers vs. nonsmokers, 6:29  
 in smokers vs. nonsmokers, 6:31  
**Mainstream smoke**  
*See SMOKE, CIGARETTE MAINSTREAM; SMOKE STREAMS*  
**MALEIC HYDRAZIDE**  
 hydrazine levels and, 14:41  
 structural formula, 14:62  
 tobacco curing and, 14:47  
**MALES**  
*(See also SEX RATIO)*  
 smoking prevalence, A:11, A:12-13, A:17-18  
**MARIJUANA**  
*(See also CANNABIS; DRUG ABUSE)*  
 correlation with tobacco smoking, 18:14  
 effect on enzyme activity, 12:42-43  
 effect on pharmacokinetics, 12:42-43  
 effect on pregnant animals, 8:53  
**MATERNAL-FETAL EXCHANGE**  
 aromatic hydrocarbons in animals, 8:66  
 benzo(a)pyrene in animals, 8:66  
 carbon monoxide in sheep, 8:59  
 carbon monoxide in sheep and dogs, 8:58  
 nicotine in animals, 8:54  
**Maternal smoking**  
*See SMOKING, MATERNAL*  
**Maximum mid-expiratory flow rate measurements**  
*See RESPIRATORY FUNCTION TESTS*  
**MECAMYLAMINE**  
 nicotine antagonist, 16:8-9  
**MEDICAL STUDENTS**  
 antismoking education, 22:17-18  
 perceptions of physicians' smoking habits, 22:7  
 smoking habits, 18:8, 22:18  
**MEDITATION**  
 in modification of smoking behavior, 19:22

## Men

*See MALES*

## MEPERIDINE

total clearance in smokers vs. nonsmokers, 12:39

## MEPROBAMATE

cessation aid, 19:17

## MERCURY

*(See also METALS)*

levels in smokers vs. nonsmokers, 12:73

smoking and occupational exposure, 7:7

## MESOTHELIOMA

*(See also CARCINOGENESIS; NEOPLASMS)*

smoking and asbestos exposure and, 7:12

## METABOLISM

*(See also NICOTINE METABOLISM)*

carbon monoxide in maintenance of smoking habit, 15:17

effect of smoking on carbohydrates, lipids and proteins, 12:65

effect of tobacco smoke on food constituents and additives, 12:75-76

nicotine in maintenance of smoking habit, 15:16

nicotine, in smokers vs. nonsmokers, 15:9

tar, in maintenance of smoking habit, 15:17

## METALS

*(See also CADMIUM; CALCIUM; LEAD; MERCURY; NICKEL)*

cardiovascular diseases and, 4:62  
 in cigarette smoke as carcinogens, 14:59-60

levels in particulate phase cigarette smoke, 14:59

levels in smokers vs. nonsmokers, 12:73-74

in tobacco smoke, 14:58-59

## METHYL PARATHION

smoking and occupational exposure, 7:7

## METHYLCHOLANTHRENE

*(See also AROMATIC HYDROCARBONS)*

effect on aryl hydrocarbon hydroxylase activity in rats, 12:28-29

effect on enzyme activity, 12:21-22

effect on phenacetin pharmacokinetics in rats, 12:28-29  
effect on RNA metabolism, 12:21-22  
effect on theophylline metabolism in rats, 12:32  
in oral neoplasm induction in hamsters, 5:42

#### **METHYLENE CHLORIDE**

occupational hazards, 7:8-9

#### **MORBIDITY**

(*See also* **MORTALITY**)

bed disability in smokers vs. nonsmokers, 3:12  
bronchitis and emphysema in the United States, 6:20  
coronary heart disease in ex-smokers, 4:38  
effect of cessation of smoking, summary of findings, 1:12-13  
effect of smoking, 3:5  
effect of smoking, summary of findings, 1:12-13  
effect of smoking on acute conditions, 3:6  
effect of smoking on chronic conditions, 3:6-7  
findings of NCHS National Health Interview Survey, 1:12-13  
incidence of acute conditions in smokers vs. nonsmokers vs. ex-smokers, 3:9  
peptic ulcer in the United States, 9:17  
prevalence rate of chronic conditions, 3:6-7  
smoking and lung neoplasms and occupational risk, 7:17  
work-days lost, 3:8-9

#### **MORBIDITY RATIO**

angina pectoris, effect of smoking levels, 4:48  
coronary heart disease in ex-smokers, 4:28-31, 4:34-35  
coronary heart disease in smokers vs. nonsmokers, 4:27-33, 4:36-37

#### **MORTALITY**

(*See also* **EXCESS DEATHS; FETAL MORTALITY; INFANT MORTALITY; LIFE EXPECTANCY; MORBIDITY; PERINATAL MORTALITY**)

annual probability of dying in smokers vs. nonsmokers vs. ex-smokers, 2:30-34  
bronchitis in cigar vs. cigarette vs. pipe smokers, 13:34  
chronic obstructive lung disease in smokers, 2:41, 6:9  
chronic obstructive lung disease in smokers vs. nonsmokers vs. ex-smokers, 6:10  
cigar and pipe smokers vs. ex-smokers, 13:8  
cigar vs. cigarette vs. pipe smokers, 13:13-14  
effect of age began smoking, 2:19  
effect of cigar smoking, 2:30, 2:35-37  
effect of environmental factors, 2:42  
effect of heredity in smoking related disease, 2:41-42  
effect of inhalation, 2:20  
effect of inhalation in cigar and pipe smokers, 13:18  
effect of nicotine and tar content, 2:22  
effect of pipe smoking, 2:30, 2:35-37  
effect of smoking in the United States, 2:9  
effect of smoking in women, 2:25  
effect of smoking levels in cigar and pipe smokers, 13:14-16  
effect of social factors, 2:42  
effect of years since quitting in ex-smokers, 2:27-34, 2:35  
emphysema in cigar vs. cigarette vs. pipe smokers, 13:34  
epidemiological studies, 2:12-15  
esophageal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:24  
ex-smokers, 2:26-30  
methods of measuring, 2:10-11  
peptic ulcer in cigar vs. cigarette vs. pipe smokers, 13:38  
peptic ulcer in smokers, 2:41, 9:10  
peptic ulcer in smokers vs. nonsmokers, 9:17  
respiratory tract infections in smokers, 2:41

risk from pregnancy and childbirth  
vs. oral contraceptive use, 12:52  
smoking and lung neoplasms and as-  
bestos exposure, 7:11

#### **MORTALITY RATES**

age groups in the United States,  
2:11  
cerebrovascular disease in male vs.  
female smokers, 4:51  
circulatory diseases, effect of oral  
contraceptives and smoking, 12:51  
coronary heart disease in ex-smokers,  
4:38  
definition, 2:10-11  
effect of cigar and pipe smoking,  
summary of findings, 1:27  
effect of less hazardous cigarettes,  
2:25  
lung neoplasms and smoking, summa-  
ry of findings, 1:16  
lung neoplasms, effect of smoking,  
5:9-11  
lung neoplasms in cigar and pipe  
smokers, 5:23  
lung neoplasms in women, 5:16-18,  
5:20  
lung neoplasms, trends in Great Brit-  
ain and the United States, 5:10-  
11  
myocardial infarct in smokers vs.  
nonsmokers, 4:35-36  
smokers vs. nonsmokers, 2:15  
thrombosis in smokers vs. nonsmok-  
ers, 4:59

#### **MORTALITY RATIO**

age groups in the United States,  
2:11, 2:17-18  
age groups worldwide, 2:17-18  
aortic aneurysm, effect of smoking  
levels, 4:55  
bladder neoplasms in smokers, 5:45-  
46  
cardiovascular diseases in cigar vs.  
cigarette vs. pipe smokers, 13:33-  
34  
cardiovascular diseases in smokers,  
2:39  
cardiovascular diseases in smokers vs.  
nonsmokers in Japan, 4:21, 4:34-  
35  
cause-specific, effect of smoking,  
2:37-41

cerebrovascular disease in cigar vs.  
cigarette vs. pipe smokers, 13:33  
cerebrovascular disease in male vs.  
female smokers, 4:51  
chronic obstructive lung disease, 6:10  
chronic obstructive lung disease in  
cigar vs. cigarette vs. pipe smok-  
ers, 13:35  
cigar vs. cigarette vs. pipe smokers,  
2:30, 2:35-36  
cigarette vs. cigar vs. pipe vs. mixed  
smokers, 13:14  
coronary heart disease in cigar vs.  
cigarette vs. pipe smokers, 13:33-  
34  
coronary heart disease in smokers,  
2:39  
coronary heart disease in ex-smokers,  
4:34-35  
coronary heart disease in smokers vs.  
nonsmokers, 4:22-26, 4:36-37  
definition, 2:10  
effect of age began smoking, 2:19-22  
effect of cigar and pipe smoking,  
1:11-12  
effect of combined tobacco product  
use, 2:39  
effect of inhalation, 2:22-24  
effect of inhalation, smoking dura-  
tion and smoking levels in wom-  
en, 2:26-27  
effect of less hazardous cigarettes,  
1:11, 2:23-25  
effect of reasons for quitting in ex-  
smokers, 2:27-29  
effect of smoking, summary of find-  
ings, 1:10-12  
effect of smoking duration, 2:17-19  
effect of smoking duration in cigar  
smokers, 2:37  
effect of smoking duration in ex-  
smokers, 2:28-29  
effect of smoking duration in pipe  
smokers, 2:38  
effect of smoking levels, 2:15-18,  
2:22  
effect of smoking levels in cigar  
smokers, 13:15-17, 2:36-37  
effect of smoking levels in ex-smok-  
ers, 2:28-29  
effect of smoking levels in pipe  
smokers, 2:36-38, 13:15-17

esophageal neoplasms in cigar and pipe smokers, 5:43

esophageal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:25

esophageal neoplasms in smokers, 5:42-43

ex-smokers, 2:35

kidney neoplasms in smokers, 5:48-49

laryngeal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:24

laryngeal neoplasms in smokers, 5:32-33

lung neoplasms, effect of age began smoking, 5:13-14

lung neoplasms, effect of cessation of smoking, 5:24-26

lung neoplasms, effect of inhalation, 5:14-15

lung neoplasms, effect of low tar and nicotine cigarettes, 5:15-17

lung neoplasms, effect of smoking levels, 5:13

lung neoplasms in cigar vs. cigarette vs. pipe smokers, 13:26-28

lung neoplasms in smokers vs. non-smokers, 5:11-12

lung neoplasms in smoking women, 5:20-22

neoplasms, effect of cigar and pipe smoking, 13:20

neoplasms in smokers, 2:38

oral neoplasms in cigar vs. cigarette vs. pipe smokers, 13:21-23

oral neoplasms in smokers, 5:39-40

pancreatic neoplasms in smokers, 5:50-52

pharyngeal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:23

in smoking twins, 2:42

sudden cardiac death, effect of smoking levels, 4:43

#### **MORTALITY RISK**

infant, and gestational age in smoking vs. nonsmoking mothers, 8:43, 8:45

infant, effect of maternal smoking, age, parity, and education, 8:33

infant, effect of maternal smoking, age, parity, and social class, 8:31

infant, synergism of maternal smoking and other risk factors, 8:35

infants of smokers vs. nonsmokers, 8:34

#### **MOTIVATION**

(See also **BEHAVIOR**)

cessation of smoking and, 18:19-20

emotional influences in smoking behavior, 16:6

maintenance of smoking and, 18:10-13, 18:15-17

smoking habit in developing countries and, 18:24

smoking habit in the Solomon Islands and, 18:24

#### **MOUTH**

nicotine absorption, 14:85

#### **MOUTH MUCOSA**

(See also **LEUKOPLAKIA**)

effect of snuff in women, 13:39-40

#### **MOUTH NEOPLASMS**

(See also **LEUKOPLAKIA**; **LIP NEOPLASMS**; **TONGUE NEOPLASMS**)

alcohol consumption and smoking and, 5:40-41

cigar and pipe smoking and, summary of findings, 1:27

#### **MUCOCILIARY SYSTEM**

(See also **CILIARY ACTIVITY**; **CILIATOXICITY**)

effect of cigarette smoke, 6:32-33, 10:15

#### **MULTICOMPONENT TREATMENT**

(See also **CESSATION OF SMOKING**)

in cessation of smoking, 16:16-17, 16:19

evaluation, 19:36

modification of smoking behavior, 19:27-28

self-administered, 19:29

#### **MULTIPLE RISK FACTOR INTERVENTION TRIAL**

effect on cessation of smoking, 19:15

#### **MUTAGENS**

in atherosclerosis etiology, 4:10

#### **MYOCARDIAL INFARCT**

(See also **CORONARY HEART DISEASE**)

animal models, 4:20

atherosclerosis in etiology of, 4:19-20

cessation of smoking after, 19:14

effect of oral contraceptives and smoking on risk, 4:60

effect of smoke inhalation in dogs, 14:77

effect of smoking on risk of recurrence or death, 4:37-38  
estrogens and smoking and, 12:52  
ex-smokers, 4:21  
ischemia and, 4:19-20, 4:39-40  
morbidity ratios in ex-smokers, 4:34  
morbidity ratios in smokers vs. non-smokers, 4:27-33  
oral contraceptives and smoking and, 4:35, 12:51-52  
pathogenesis, 4:18-20  
research needs, 4:40-41  
risk factors, 4:20-21  
smokers vs. nonsmokers, 4:35-36  
smoking in etiology of, 4:21, 4:38-40  
smoking vs. nonsmoking women, 12:52  
sudden cardiac death and, 4:43

#### **MYOCARDIUM**

effect of hypoxia and ischemia, 4:19-20

#### **NAPHTHALENE**

in cigarette smoke, 14:51  
tobacco pyrolysis and, 14:49

#### **NAPHTHYLAMINES**

(*See also* **AROMATIC AMINES**)

pancreatic neoplasms and, 5:51

#### **NATIONAL ASSOCIATION OF SECONDARY SCHOOL PRINCIPALS**

statement on school smoking policies, 23:8, 23:11, 23:13

#### **NATIONAL CANCER INSTITUTE**

funding of "Know Your Body" Program, 21:20

#### **NATIONAL CENTER FOR HEALTH STATISTICS, 3:5**

findings of National Health Interview Survey, 1:12-13

Health and Nutrition Examination Survey, 3:11-12

Health Interview Survey, 3:8-18

#### **NATIONAL CLEARINGHOUSE FOR SMOKING AND HEALTH**

definition of smokers and nonsmokers, 23:24

establishment of San Diego Community Laboratory, 20:14

Health Consequences of Smoking reports, 1:9-10

smoking prevalence in adults by educational level, A:14-16

smoking prevalence in adults by family income, A:14-16  
survey of adolescent smoking, 17:7-8  
survey of adult tobacco use, 18:19, 22:6

survey of cigar and pipe smoking in the United States, 13:8-9

survey of smoking attitudes of health professionals, 22:7

survey of smoking habits of health professionals, 22:12-13

survey of tar and nicotine levels of cigarette brands, 3:11

survey of teenage smoking, A:14

training of health educators, 23:32

#### **NATIONAL INSTITUTES OF HEALTH**

respiratory disease study, 17:15

#### **NATIONAL INTERAGENCY COUNCIL ON SMOKING AND HEALTH**

funding of youth antismoking projects, 20:24

research guidelines, 19:5-8, 21:16-17

#### **NATIONAL PARENT-TEACHER ASSOCIATION**

health education programs, 21:21, 21:25

#### **NEONATAL MORTALITY**

(*See also* **INFANT MORTALITY; MORTALITY RISK; PERINATAL MORTALITY**)

effect of maternal smoking and gestational age, 8:43

effect of maternal smoking and other factors, 8:41

etiology of perinatal death in smokers vs. nonsmokers, 8:37

maternal smoking and, research needs, 8:76

maternal smoking levels and, 8:39-40

#### **NEOPLASMS**

(*See also* **CARCINOGENESIS; LEUKEMIA; MESOTHELIOMA**)

aryl hydrocarbon hydroxylase inducibility and smoking and, 5:57

cigar and pipe smoking and, summary of findings, 1:27-28

effect of smoking on mortality ratio, 2:38

induced by polonium-210 in Syrian hamsters, 14:61

induced by tobacco smoke in animals, 1:17

mortality ratio in cigar and pipe smokers, 13:20  
 nitrosamines in etiology of, 12:74  
 in progeny after maternal exposure to benzo(a)pyrene in mice, 8:67  
 smoking and, summary of findings, 1:15-17  
 smoking and asbestos exposure and, 7:11-13  
 smoking in etiology of, historical perspective, 5:9  
**Neoplasms, bronchial**  
   *See* **BRONCHIAL NEOPLASMS**  
**Neoplasms, esophageal**  
   *See* **ESOPHAGEAL NEOPLASMS**  
**Neoplasms, laryngeal**  
   *See* **LARYNGEAL NEOPLASMS**  
**Neoplasms, lip**  
   *See* **LIP NEOPLASMS**  
**Neoplasms, lung**  
   *See* **LUNG NEOPLASMS**  
**Neoplasms, mouth**  
   *See* **MOUTH NEOPLASMS**  
**Neoplasms, pancreatic**  
   *See* **PANCREATIC NEOPLASMS**  
**Neoplasms, pharyngeal**  
   *See* **PHARYNGEAL NEOPLASMS**  
**Neoplasms, oral**  
   *See* **ORAL NEOPLASMS**  
**Neoplasms, tongue**  
   *See* **TONGUE NEOPLASMS**  
**NEUROTICISM**  
   (*See also* **ANXIETY; STRESS**)  
   cessation of smoking and, 18:17-18  
   maintenance of smoking and, 18:7-9  
   smoking characteristics and, 18:13  
**NICKEL**  
   (*See also* **METALS**)  
   levels in tobacco smoke, 14:59  
   and smoking in lung neoplasm etiology, 5:28  
**NICOTINE**  
   (*See also* **ALKALOIDS, TOBACCO**)  
   absorption by involuntary smoking, 11:24  
   addiction, 16:7-9, 18:12  
   in allergy induction, 10:22  
   in amniotic fluid after maternal injection in animals, 8:54  
   in atherosclerosis induction in animals, 4:16  
   cardiovascular diseases and, 14:79  
   carotid blood levels after oral administration, 14:86  
   central nervous system receptor sites, 16:18-19  
   dependence and, 14:97  
   effect of cigar smoke inhalation on absorption, 13:16-17  
   effect of fetal injection in utero in animals, 8:55  
   effect of maternal injection on fetus in animals, 8:54-57  
   effect of maternal injection on nursing kittens, 8:49  
   effect of maternal injection on offspring in rats, 8:10-11  
   effect of maternal injection on psychomotor function in newborn animals, 8:57  
   effect of self-administration on smoking habit, 15:12  
   effect of smoking characteristics on absorption, 14:87  
   effect on angina pectoris, 4:39  
   effect on antidiuretic hormone secretion, 12:37, 12:54  
   effect on arousal, 15:11  
   effect on arteries in rabbits, 4:56  
   effect on behavior in monkeys, 15:12  
   effect on behavior in rats, 15:11, 15:18  
   effect on birth weight in animals, 8:53  
   effect on blood lipid levels in animals, 4:61  
   effect on blood pressure and heart rate, 4:58, 14:87, 14:91  
   effect on cardiovascular system, 12:52-54, 14:89  
   effect on cardiovascular system in animals, 8:55-56  
   effect on cardiovascular system in animals with myocardial infarct, 4:45  
   effect on catecholamines in rats, 14:88  
   effect on central nervous system, 14:89  
   effect on cerebrovascular circulation, 4:50  
   effect on corticosteroid secretion, 12:40  
   effect on drug assays, 12:34

effect on enzyme activity, 12:27-28, 14:87  
 effect on enzyme activity in rat intestines, 12:76  
 effect on exercise induced angina pectoris, 4:47  
 effect on fetal and newborn central nervous system, 8:57  
 effect on fetal and newborn central nervous system in animals, 8:56  
 effect on fetus, research needs, 8:79  
 effect on fetus and breastfed infants of smoking mothers, 8:51  
 effect on free fatty acids, 12:40, 14:90  
 effect on gastric secretion in cats, 9:12-13  
 effect on gastric secretion in man, 9:13-14  
 effect on heart function in animals with coronary heart disease, 4:40  
 effect on hormones in monkeys, 15:20  
 effect on immunoglobulins, 6:31  
 effect on ischemia, 4:39  
 effect on lactation in cats, 8:49  
 effect on lactation in cows, 8:49  
 effect on lactation in rats, 8:49  
 effect on lung function, 14:90  
 effect on lymphocytes in mice, 10:19  
 effect on nitrosamine biosynthesis, 12:75  
 effect on pancreatic secretion in dogs, 5:53, 9:14-15  
 effect on patellar reflex, 14:92  
 effect on pharmacokinetics, 12:27-28  
 effect on psychomotor performance, 16:8  
 effect on pregnant rats, 8:10-11  
 effect on serum secretin levels, 9:14-15  
 effect on smoking habit, 15:7-8  
 effect on smoking habit, summary of findings, 1:30-32  
 effect on tolerance in rats, 15:16  
 effect on vitamin C levels in animals, 12:66  
 in establishing smoking habit, 15:5  
 excretion under stress, 16:8  
 induction of hyperglycemia in cats, 14:90  
 induction of peptic ulcer in cats, 9:12-13

induction of peptic ulcer in rats, 9:12  
 interactive effect with oxprenolol on blood pressure, 12:54  
 interactive effect with propranolol on cardiovascular system, 12:53  
 internal regulation in smokers, 16:13-14  
 in maintenance of smoking habit, 15:14  
 maternal-fetal exchange in animals, 8:54  
 metabolism in maternal and fetal liver in animals, 8:55  
 metabolism in smokers vs. nonsmokers, 15:9  
 methods of absorption, 14:85  
 myocardial infarct and, 4:20  
 pancreatic neoplasms and, 5:53  
 pharmacology in cessation of smoking, 14:94, 14:97  
 protonation and, 14:108  
 as reinforcer, 16:12, 16:18  
 relative molar potency in cigarette smoke, 14:96  
 role as hapten, 10:11  
 role in alteration of drug metabolism, 12:40  
 sales weighted average delivery in American cigarettes, 14:111  
 smoke dosimetry and, 14:75  
 structural formula, 14:46  
 summary of physiological effects, 1:30-31

**NICOTINE CONTENT**  
 (See also **ALKALOID CONTENT**)  
 in blood, effect of smoking cigarettes vs. little cigars, 14:87  
 in blood after oral administration, 14:86  
 in cigar vs. cigarette smoke, 13:11  
 in cigarette smoke, 14:45  
 in cigarettes, health characteristics and, 3:11  
 in cigarettes vs. little cigars, 14:44-45  
 in cow's milk after intramuscular injection, 8:49  
 decrease in modern cigarettes, A:19-20  
 effect on mortality, 2:22  
 filters and, 14:104  
 in milk of lactating smoking vs. non-smoking mothers, 8:50-51

- as smoke inhalation indicator, 14:75
- in urine and plasma of smokers vs. nonsmokers, 11:24
- in urine as measure of tobacco usage, 15:29
- in urine of smokers vs. nonsmokers, 15:29
- NICOTINE CHEWING GUM**
  - in cessation of smoking, 19:16-17
  - in reduction of smoking, 16:8
- NICOTINE-IN-SALIVA TEST**
  - correlation with self-reported smoking, 17:24
- NICOTINE METABOLISM**
  - (See also **METABOLISM**)
  - degree of protonation in relation to pH, 14:86
  - distribution and clearance in rats, 14:79
  - effect of urinary pH on excretion, 14:92-93
  - enzymes and, 14:87
  - pathway, 14:93
  - rate of absorption, 14:92
- NICOTINE METABOLITES**
  - (See also **COTININE**; **NORNICOTINE**)
  - in cigarette smoke, 14:93-94
  - effect of urinary pH on excretion, 14:92
- NICOTINE REDUCTION**
  - in cigarettes in the United States, 14:44
  - effect on lung neoplasm mortality ratio, 5:15-16
  - methods, 14:114
  - in particulate phase of cigarette smoke, 14:108
- NICOTINE TOXICITY**
  - atherosclerosis and, 14:79
  - effect on heart, 14:78
  - effect on smoke inhalation dosimetry, 14:75
  - hypertension and, 14:79
- NITRIC OXIDE**
  - in blood of smokers vs. nonsmokers, 14:80
  - effect on enzyme activity in rats, 14:81
- NITRILES**
  - levels in cigarette smoke, 14:40
- NITROGEN COMPOUNDS**
  - in cigarette smoke, 14:41
  - in soil, effect on tobacco leaf quality, 14:15-16
- NITROGEN DIOXIDE**
  - effect on antibody response to bacterial vaccines in mice, 12:59
  - effect on respiratory tract in rats, 14:81
- NITROGEN OXIDES**
  - absorption, 14:99
  - cardiovascular diseases and, 4:62
  - content in mainstream cigarette smoke, 14:39
- NITROSAMINE CONTENT**
  - in cigarette smoke, 14:39, 14:45
  - effect of curing and fermentation, 14:45
  - effect of homogenized leaf curing, effect of smoking in enclosed spaces, 11:25
  - reduction in gas phase cigarette smoke, 14:107
  - reduction in particulate phase cigarette smoke, 14:112
  - in tobacco and tobacco smoke, 12:74
- NITROSAMINES**
  - (See also **DIMETHYLNITROSAMINE**)
  - agricultural practices and, 14:107
  - biosynthesis in smokers, 12:74-75
  - bladder neoplasms and, 5:47
  - in chewing tobacco, 14:45
  - effect of maternal injection on tracheal neoplasms in hamster offspring, 8:50
  - effect of nicotine on biosynthesis, 12:75
  - in esophageal neoplasm induction in animals, 5:44
  - in lung neoplasm induction in hamsters, 5:30
  - in neoplasm etiology, 12:74
  - in pancreatic neoplasm induction in hamsters, 5:51-53
  - precursors, 14:41
  - quantification by thermal energy analyzer, 14:11
  - in respiratory tract neoplasm induction in animals, 5:30
  - structural formulae, 14:46

## **NONSMOKERS**

(See also **SMOKERS VS. NON-SMOKERS**)

- absorption of tobacco smoke constituents, 11:6
- annoyance caused by tobacco smoke, 11:25
- annual probability of dying, 2:30-34
- effect of involuntary smoking, 11:5, 11:15, 11:28
- effect of involuntary smoking on carboxyhemoglobin levels, 11:21, 11:23
- effect of tobacco smoke, 11:25
- median carboxyhemoglobin levels by location, 11:23
- nicotine absorption by involuntary smoking, 11:24
- perception of health status, 3:14-15
- rights, 16:19-20, 21:14, 21:18
- typology, 18:13

## **NORNICOTINE**

(See also **NICOTINE METABOLITES**)

- relative molar potency in cigarette smoke, 14:96
- structural formula, 14:46

## **NORTRIPTYLINE**

- plasma concentrations in smokers vs. nonsmokers, 12:39

## **NOSE IRRITATION**

- effect of smoking in enclosed spaces, 11:26

## **NURSES**

- role in cessation decision, 21:12, 21:14, 22:17
- smoking habits, 22:12-14

## **NURSING HOMES**

- smoking policies, 22:20

## **OBESITY**

(See also **BODY WEIGHT**)

- cessation of smoking and, 12:67

## **OBSTRUCTIVE AIRWAY DISEASES**

(See also **BRONCHITIS; BRONCHOPULMONARY DISEASES;**

**CHRONIC OBSTRUCTIVE LUNG DISEASE; EMPHYSEMA**)

- smoking in cotton workers and, 7:9-10
- smoking in fire fighters and, 7:10-11
- smoking in miners and, 7:9

## **OCCUPATIONAL DISEASES**

(See also **ASBESTOSIS; BYSSINOSIS; NEOPLASMS; POLYMER FUME FEVER**)

- asbestosis, 7:11-13
- byssinosis, 7:9
- "Monday morning fever", 7:9
- polymer fume fever, 7:5-6
- OCCUPATIONAL EXPOSURE**
  - bronchopulmonary diseases and, 1:19, 6:36, 7:13
  - interactive effect with smoking, summary of findings, 1:19-20
  - smoking and bladder neoplasms and, 5:47
  - smoking and pancreatic neoplasms and, 5:47
  - and smoking in lung neoplasm etiology, 5:27-29
  - smoking levels and health risk, 7:17

## **OCCUPATIONAL HAZARDS**

- alpha irradiation from radon, 7:14
- aromatic amines, 7:16
- asbestos, 7:11-13
- beta radiation, 7:10
- carbon monoxide, 7:8
- chlorine, 7:10
- chloromethyl ether, 7:15-16
- dust, coal, 7:9
- dust, cotton, 7:9
- dust, gold, 7:15
- effect of smoking and recommendations for research, 7:19
- hydrogen cyanide, 7:7-8
- rubber, 7:13

## **OCCUPATIONS**

- asbestos workers, 5:28, 7:11-13
- battery factory workers, 7:15
- benzene workers, 14:51
- blast furnace workers, 7:8
- blue- and white-collar workers, 7:17
- bronchitis in smokers vs. nonsmokers and, 6:39
- chemists, 5:51
- chlorine workers, 7:10
- chloromethyl ether workers, 5:29, 7:15-16
- coal gas workers, 7:16
- coal miners, 13:35
- cotton workers, 7:9
- electroplaters, 7:7
- fire fighters, 7:10-11
- gold miners, 7:15

industrial workers, 22:16-17, 22:19  
insulation workers, 7:11  
methylene chloride workers, 7:8-9  
miners, 7:9  
nickel workers, 5:28  
rubber workers, 7:13  
smoking prevalence rates and, 18:16,  
A:16  
steelworkers, 7:8  
telephone workers, 6:37  
tobacco workers, female, 8:9  
uranium miners, 5:28, 7:14, 12:90  
**OFFICE ON SMOKING AND  
HEALTH**  
information dissemination function,  
23:27-28

#### **Olefins**

*See* ALKENES

#### **ONTARIO PERINATAL MORTALITY STUDY, 8:33-35, 8:37, 8:39-42, 8:45**

#### **ORAL NEOPLASMS, 5:39-42**

(*See also* LEUKOPLAKIA; LIP  
NEOPLASMS; MOUTH NEO-  
PLASMS; TONGUE NEOPLASMS)

alcohol consumption and smoking  
and, 5:40-41  
animal models, 5:41-42  
betel chewing in etiology of, 13:40-  
41  
cigar and pipe smoking and, 5:39  
induced by benzo(a)pyrene in ham-  
sters, 5:42  
induced by dimethyl benzantracene  
in hamsters, 5:42  
induced by methylcholanthrene in  
hamsters, 5:42  
mortality ratio in cigarette vs. cigar  
vs. pipe smokers, 13:21-23  
mortality ratio in smokers, 5:39-40  
smoking and, summary of findings,  
1:17  
smoking in etiology of, 5:39-42  
snuff in etiology of, 13:39-40  
tobacco chewing and, 5:39-40  
tobacco chewing in etiology of,  
13:40-41

#### **ORALITY**

smoking habit and, 18:9

#### **ORGANOTIN**

smoking and occupational exposure,  
7:7

#### **OSTEOPOROSIS**

smokers vs. nonsmokers, 12:67

#### **OXPRENOLOL**

interactive effect with nicotine on  
blood pressure, 12:54

#### **OXYGEN TENSION**

effect of maternal and fetal carbox-  
yhemoglobin levels, 8:64

#### **OXYGEN TRANSPORT**

effect of carbon monoxide in mother  
and fetus, 8:61

#### **OXYHEMOGLOBIN SATURATION CURVES**

maternal and fetal, effect of carbon  
monoxide levels in blood, 8:62-63,  
8:72

#### **PANCREATIC NEOPLASMS**

animal models, 5:51-53  
correlation with bladder neoplasms,  
5:47  
diet and, 5:51  
effect of smoking levels on mortality  
and risk ratios, 5:50, 5:52  
effect of smoking and occupational  
exposure, 7:17  
induced by nitrosamines in hamsters,  
5:51-53  
mortality and risk ratios in male vs.  
female smokers, 5:50-52  
naphthylamines and, 5:51  
nicotine and, 5:53  
occupational exposure and, 5:51  
smoking and, summary of findings,  
1:17

#### **PANCREATIC SECRETION**

effect of nicotine in animals and  
man, 9:14-15  
effect of nicotine in dogs, 5:53  
effect of smoking, 9:14-15

#### **Paper, cigarette**

*See* CIGARETTE PAPER

#### **Parental smoking**

*See* SMOKING, PARENTAL

#### **PARKINSONISM**

smoking and, 2:41

#### **PARTICULATE PHASE, CIGARETTE SMOKE**

(*See also* TARS, TOBACCO; TO-  
TAL PARTICULATE MATTER)

aromatic hydrocarbons reduction,  
14:109  
component levels, 15:6  
definition, 14:35, 14:38  
determination of tar levels, 14:43

levels of toxic compounds, 14:64-65  
 levels of metals, 14:59  
 nicotine reduction, 14:108  
 nitrosamines reduction, 14:112  
 ratio of constituents in main- vs. sidestream smoke, 11:6  
 polonium-210 reduction, 14:113  
 tar reduction methods, 14:110  
 toxicity reduction, 14:108  
 toxicity reduction methods, 14:114  
**Passive smoking**  
*See INVOLUNTARY SMOKING*  
**Peak expiratory flow measurements**  
*See RESPIRATORY FUNCTION TESTS*  
**PEER GROUPS**  
 influence on cessation of smoking, 18:21  
 influence on drug abuse in adolescents, 18:14  
 influence on initiation of smoking, 16:5  
 influence on smoking habit in adolescents, 17:10, 17:14, 21:13-14  
 youth-to-youth antismoking programs, 20:9  
**PENTAZOCINE**  
 dosage requirements in smokers vs. nonsmokers, 12:36  
**Peptic ulcer**  
*See ULCER, PEPTIC*  
**PERINATAL MORTALITY**  
*(See also INFANT MORTALITY; MORTALITY RISK; NEONATAL MORTALITY)*  
 effect of maternal smoking, summary of findings, 1:22  
 gestational age and risk in smoking vs. nonsmoking mothers, 8:43  
 maternal smoking in etiology of, 12:67  
 maternal smoking levels and, 8:39-40  
**PERIPHERAL VASCULAR DISEASE**  
 animal models, 4:53  
 clinical and pathological features, 4:52  
 research needs, 4:54  
 risk factors, 4:52  
 smoking and, summary of findings, 1:14-15  
 smoking and, 4:53-54  
 smoking vs. nonsmoking diabetics, 4:53

## **PERSONALITY**

*(See also BEHAVIOR)*

cessation of smoking and, 18:17-18, 18:21-22  
 effect on pharmacokinetics, 12:40-41  
 effect on success rates for cessation of smoking, 15:24  
 maintenance of smoking and, 18:5-10  
 maternal smoking and, 8:26  
 and recidivism, 19:31  
 and smoking habits in adolescents, 17:16

## **PESTICIDE RESIDUES**

hydrazine formation, 14:41  
 reduction in tobacco, 14:61  
 structural formulae, 14:62  
 in tobacco leaf, 14:18  
 in tobacco smoke, 12:75  
 toxic effects in smokers, 12:75

## **pH**

cigar vs. cigarette vs. pipe smoke, 13:15-16

## **PHAGOCYTOSIS**

*(See also MACROPHAGES, ALVEOLAR)*

effect of tobacco smoke, 6:30-31  
 role in lung neoplasm etiology, 5:31

## **PHARMACISTS**

antismoking advice to customers, 22:17

as role models, 22:8-9

smoking habits, 22:12

## **PHARMACODYNAMICS**

*(See also DRUG METABOLISM; PHARMACOLOGY)*

absence of smoking effect, 12:37-39  
 clinical importance of smoking history in drug monitoring, 12:41-42  
 dexamethasone, effect of smoking, 12:37

diazepam, effect of smoking, 12:38

effect of smoking, 12:27-44

effect of smoking, summary of findings, 1:25-26

furosemide, effect of smoking, 12:37

propranolol, effect of smoking, 12:37

research needs, 12:44

smokers vs. nonsmokers, 12:36-37

## **PHARMACOKINETICS**

*(See also DRUG METABOLISM; PHARMACOLOGY)*

absence of smoking effect, 12:37-39

antipyrine, in smokers vs. nonsmokers, 12:29-31

caffeine, effect of aromatic hydrocarbons in rats, 12:32-33

clinical importance of smoking history in drug monitoring, 12:41-42

effect of behavior and personality, 12:40-41

effect of marijuana, 12:42-43

effect of smoking, 12:27-44

effect of smoking, summary of findings, 1:25-26

ethanol, in smokers vs. nonsmokers, 12:39

glutethimide, in smokers vs. nonsmokers, 12:33

imipramine, effect of smoking, 12:33

meperidine, in smokers vs. nonsmokers, 12:39

nortriptyline, in smokers vs. nonsmokers, 12:39

pentazocine, in smokers vs. nonsmokers, 12:36

phenacetin, effect of cigarette smoke in rats, 12:28-29

phenacetin, in smokers vs. nonsmokers, 12:28-29

phenytoin, in smokers vs. nonsmokers, 12:38

research needs, 12:44

theophylline, effect of methylcholanthrene in rats, 12:32

theophylline, in smokers vs. nonsmokers, 12:31-32

warfarin, effect of benzo(a)pyrene in rats, 12:38

warfarin, in smokers vs. nonsmokers, 12:38

## PHARMACOLOGY

(See also PHARMACODYNAMICS; PHARMACOKINETICS)

carbon monoxide in establishing smoking habit, 15:7

cigarette smoke, 14:85, 14:94, 14:97-99

dependence and tolerance in maintenance of smoking habit, 15:14

nicotine in establishing smoking habit, 15:5, 15:7-8

tar in establishing smoking habit, 15:7

tobacco alkaloids, 14:94

## PHARYNGEAL NEOPLASMS

(See also RESPIRATORY TRACT NEOPLASMS)

alcohol consumption and smoking and, 5:40-41

mortality in cigar vs. cigarette vs. pipe smokers, 13:22-23

## PHENACETIN

effect of cigarette smoke on pharmacokinetics in rats, 12:28-29

effect of methylcholanthrene on pharmacokinetics in rats, 12:28-29

pharmacokinetics in smokers vs. nonsmokers, 12:28-29

## PHENOLS

in cigarette smoke condensate, 14:52

effect of filters, 14:54

effect on ciliary activity, 14:81

levels in cigar vs. cigarette smoke, 13:11-12

levels in smoke of filtered vs. nonfiltered cigarettes, 14:57

reduction of levels in gas phase cigarette smoke, 14:106

structural formulae, 14:56

## PHENYLBUTAZONE

effect of smoking on pharmacokinetics, 12:33

## PHENYTOIN

pharmacokinetics in smokers vs. nonsmokers, 12:38

## PHYSICAL ACTIVITY

(See also EXERCISE)

effect on coronary heart disease incidence in smokers, 4:38

## PHYSICAL DEVELOPMENT

effect of maternal smoking on children, 1:21

## PHYSICIAN VISITS

smokers vs. nonsmokers vs. ex-smokers, 3:15, 3:17

## PHYSICIANS

as health educators, 22:15-16

role in cessation decision, 19:12-14, 21:11-12, 21:14, 22:19, 22:22

as role models, 22:6-8

in school antismoking programs, 20:9-10

smoking habits, 21:12, 22:9-14

## Pipe

*See* SMOKE, PIPE; SMOKERS, PIPE; SMOKING, PIPE; TOBACCO, PIPE

## PLACENTA

aryl hydrocarbon hydroxylase activity after maternal exposure to benzo(a)pyrene in rats, 8:66  
effect of maternal smoking, 8:69  
effect of maternal smoking, research needs, 8:78

## PLACENTA PREVIA

gestational age and risk in smoking vs. nonsmoking mothers, 8:44, 8:46  
maternal smoking levels and, 8:39  
maternal smoking levels and perinatal mortality, 8:40

## PLACENTAL RATIO

effect of maternal smoking, 8:14-18  
effect of oxygen availability, 8:17  
in smokers vs. nonsmokers, 8:15-16, 8:18

## POLONIUM-210

cardiovascular diseases and, 4:62  
levels in cigarette smoke, 14:60  
levels in smokers vs. nonsmokers, 12:74-75  
neoplasm induction in Syrian hamsters, 14:61  
reduction in particulate phase cigarette smoke, 14:113  
in tissues of smokers vs. nonsmokers, 14:60-61  
as tobacco contaminant, 14:20-21

## POLYCYTHEMIA

smoking in etiology of, 12:83

## POLYMER FUME FEVER

*(See also* OCCUPATIONAL DISEASES)

smoking and, 7:5-6

## PREECLAMPSIA

maternal smoking and, research needs, 8:77  
maternal smoking levels and, 8:42

## PREGNANCY

*(See also* PRETERM DELIVERY)

accidental hemorrhage in smokers vs. nonsmokers, 8:39  
cessation of smoking during, 22:16, 22:18, 22:23  
complications, research needs, 8:76-77

smoking and abruptio placentae and placenta previa, 8:39

smoking and bleeding, 8:39

smoking and premature membrane rupture, 8:39

gestational age and premature membrane rupture in smokers vs. nonsmokers, 8:44, 8:46

smoking levels and abruptio placentae, bleeding, placenta previa and premature membrane rupture, 8:39-41

smoking levels and perinatal mortality, 8:40

## PRETERM DELIVERY

effect of maternal smoking levels, 8:43

and infant mortality risk in smoking vs. nonsmoking mothers, 8:42

maternal smoking and, 1:22

in smoking vs. nonsmoking mothers, 8:42

## PREVENTION OF SMOKING

*(See also* ANTISMOKING CAMPAIGNS; CESSATION OF SMOKING)

communication models, 17:11-12  
recommendations for the future, 17:22-25

summary of methodologies and programs, 1:33-34

Swedish 25-year program, 17:21-22  
youth programs, 17:6, 17:17-22

## PROPOXYPHENE

clinical effect in smokers vs. nonsmokers, 12:36-37

## PROPRANOLOL

interactive effect with cigarette smoke on airways, 12:54

interactive effect with nicotine on cardiovascular system, 12:53

interactive effect with smoking on cardiovascular system, 12:37

## PROSTAGLANDINS

effect of cigarette smoke on metabolism in lungs in rabbits, 12:39

## PROTEINS

effect of smoking on metabolism, 12:65-66

synthesis, role in enzyme induction, 12:21-22

## PROTONATION

nicotine in relation to pH, 14:86

nicotine reduction and, 14:108

**PSYCHOMOTOR PERFORMANCE**  
 effect of carbon monoxide, 11:28, 11:34  
 nicotine deficit and, 16:8

**PUBLIC HEALTH CIGARETTE SMOKING ACT, A:7**

**Pulmonary alveolar macrophages**  
*See* **MACROPHAGES, ALVEOLAR**

**Pulmonary clearance**  
*See* **CILIARY ACTIVITY; LUNG FUNCTION**

**Pulmonary function**  
*See* **LUNG FUNCTION**

**PYLORIC PRESSURE**  
 effect of smoking, 9:16

**RADIATION**  
 alpha exposure from radon as occupational hazard, 7:14  
 beta exposure as occupational hazard, 7:10  
 bladder neoplasms and smoking and, 12:90  
 and cigarette tars in neoplasm induction in mice, 7:10  
 laryngeal neoplasms and smoking and, 12:90  
 and smoking in lung neoplasm etiology, 5:23  
 synergistic effect with smoking on respiratory tract, 12:90

**RADIOELEMENTS**  
 levels in tobacco and tobacco smoke, 14:60  
 reduction in particulate phase cigarette smoke, 14:113  
 as tobacco contaminants, 14:20-21

**RADIUM-226**  
 levels in cigarette smoke, 14:60  
 as tobacco contaminant, 14:20-21

**Rapid smoking**  
*See* **AVERSIVE THERAPY**

**RECIDIVISM**  
 carboxyhemoglobin levels as measure of, 15:29-30  
 cognitive and physiological factors, 16:18  
 post-treatment followup, 19:8  
 prevention, 19:30-31, 19:35  
 rates in cessation programs, 21:15-17  
 withdrawal state and, 16:18

**Reconstituted tobacco sheet**  
*See* **TOBACCO SHEET**

**REFLEXES**  
 effect of nicotine, 14:92

**Relative molar potency**  
*See* **MOLAR POTENCY**

**RELIGION**  
 church attendance and motivation for smoking, 18:11  
 effects of beliefs on tobacco consumption, 18:24

**RESPIRATORY FUNCTION TESTS**  
*(See also* **LUNG FUNCTION***)*  
 in smokers vs. nonsmokers vs. ex-smokers, 6:14-16

**RESPIRATORY SYMPTOMS**  
 in cigar and pipe smokers vs. nonsmokers, 13:34  
 in childhood and adult respiratory tract disease, 6:38-39  
 in cigar vs. cigarette vs. pipe smokers, 13:36-37  
 effect of air pollution in smokers vs. nonsmokers, 6:37  
 effect of smoking, 6:7  
 effect of smoking in children, 6:11-12  
 rate of decline of FEV in smokers vs. nonsmokers and, 6:22  
 in smokers vs. nonsmokers, 6:20  
 smoking and, summary of findings, 1:18-19  
 smoking and sex ratio, 6:20  
 smoking levels and, 6:20  
 in smoking vs. nonsmoking twins, 6:35

**RESPIRATORY SYSTEM**  
*(See also* **LUNGS; TRACHEA***)*  
 effect of cessation of smoking, 15:21  
 effect of inhalation in cigar and pipe smokers, 13:15-16  
 effect of nitrogen dioxide in rats, 14:81  
 effect of rapid smoking, 19:26  
 synergistic effect of uranium and smoking, 12:90

**RESPIRATORY TRACT DISEASES**  
*(See also* **LUNG DISEASES***)*  
 cessation of smoking in patients, 12:18-19  
 effect of involuntary smoking in children, 11:32

effect of parental smoking on incidence in children, 11:33-34  
 effect of smoking and history of childhood respiratory symptoms, 6:38-39  
 mass media preventive campaign, 21:10  
 smoking and, 6:7  
 smoking history of young adults and, 6:12  
 smoking in children and, 6:11-12  
**RESPIRATORY TRACT INFECTIONS**  
 allergic predisposition and smoking, 10:22  
 effect of parental smoking on incidence in children, 10:12, 11:32  
 effect of passive smoking in infants, 8:45  
 effect of smoking on mortality, 2:41  
 in smokers vs. nonsmokers, 6:20  
 smoking levels and, 6:30  
**RESPIRATORY TRACT MUCOSA**  
 effect of smoking, 10:14  
**RESPIRATORY TRACT NEOPLASMS**  
 (See also LARYNGEAL NEOPLASMS; LUNG NEOPLASMS; PHARYNGEAL NEOPLASMS; TRACHEAL NEOPLASMS)  
 smoking in uranium miners and, 7:14  
**RNA**  
 effect of methylcholanthrene on metabolism, 12:21-22  
 role in enzyme induction, 12:21-22  
**ROBERT WOOD JOHNSON FOUNDATION**  
 Health Activities Project, 21:20  
**ROLE MODELS**  
 (See also PARENTAL SMOKING; PEER GROUPS; SIBLING SMOKING; TEACHERS; HEALTH PROFESSIONALS)  
 in cessation of smoking, 18:21, 22:6-9  
 influence on smoking in adolescents, 17:11, 20:6, 21:11-14, 23:35  
**RUBBER**  
 occupational hazards, 7:13  
**SALIVA**  
 nicotine and thiocyanates in smokers vs. nonsmokers, 15:30  
**SAN DIEGO COMMUNITY LABORATORY**  
 program description, 20:14-15, 21:25

**SASKATOON SMOKING STUDY**  
 description 20:11-12, 23:25  
**SATURATED FATS**  
 in atherosclerosis induction in animals, 4:9  
**SCHICK SMOKING CONTROL CENTERS**  
 cessation program, 21:16  
**SCHOOL HEALTH CURRICULUM PROJECT**  
 community agency involvement, 23:15  
 curriculum development approach, 23:19  
 description, 20:18-22  
 evaluation, 17:19-20, 20:25  
 parental involvement, 21:19  
 teacher training, 23:21-23, 23:32  
**SCHOOL HEALTH EDUCATION STUDY**  
 antismoking education component, 23:18  
**SCHOOL PROGRAMS**  
 (See also names of individual programs)  
 antismoking education, 20:5-22  
 colleges, 21:9-11  
 curriculum theory, 23:16-22  
 effect on students' smoking habits, 17:15  
 evaluation, 17:18-21, 20:24-25, 23:23-25  
 influence on parents, 21:19-21  
 recommendations for the future, 23:36-39  
 smoking policies, 23:8-15  
 state health education laws, 23:5-7  
 teaching methods, 23:25-27  
**SECRETIN RELEASE**  
 effect of nicotine, 9:14-15  
 effect of smoking, 9:15-16  
**SELF-REPORTS**  
 (See also VERBAL REPORT)  
 carboxyhemoglobin levels as indicator of accuracy, 3:12  
 validity, 17:24, 19:6-7, 19:33, 21:23  
**SENSORY DEPRIVATION**  
 cessation of smoking and, 19:18-19  
**SERUM IMMUNOGLOBULIN LEVELS**  
 effect of smoking, 10:18  
**SERUM PRECIPITINS**  
 in smokers vs. nonsmokers, 10:11

## SEVENTH DAY ADVENTISTS

5-Day Plan (cessation program),

19:10, 21:15-16

## SEX RATIO

absenteeism and, 3:8, 3:13

adolescent smoking, 17:7, 17:13,  
18:16, 21:25

bed disability in smokers vs. non-  
smokers, 3:12

bladder neoplasms in smokers, 5:45-  
47

cessation of smoking and, 3:18, 18:21

cessation of smoking and alcohol con-  
sumption, 18:20

cessation of smoking and personality,  
18:17-18

chronic obstructive lung disease and,  
6:7

consumption of cigarettes, cigars,  
snuff, pipe and chewing tobacco  
in the United States, 14-13

coronary heart disease morbidity ra-  
tios in smokers vs. nonsmokers  
vs. ex-smokers, 4:28-30

coronary heart disease mortality ra-  
tios in smokers vs. nonsmokers,  
4:24

effect of less hazardous cigarettes on  
mortality, 2:24-25

heart conditions and, 3:19

high density lipoprotein levels in  
smokers vs. nonsmokers, 4:61-62

laryngeal neoplasm risk in smokers  
and ex-smokers, 5:33, 5:35-38

lung function, 6:21-22

lung function in ex-smokers, 6:23

lung neoplasm mortality ratio in low  
tar and nicotine cigarette smok-  
ers, 5:16-17

lung neoplasm mortality ratio in  
smokers, 5:11-12

lung neoplasm risk in filtered vs. un-  
filtered cigarette smokers, 5:16,  
5:18-19

pancreatic neoplasm mortality and  
risk ratios in smokers, 5:50-52

prevalence of acute conditions in  
smokers vs. nonsmokers, 3:9

prevalence of chronic conditions in  
smokers vs. nonsmokers, 3:7

prevalence of chronic obstructive pul-  
monary disease, 6:20

recidivism and, 19:31

smoking and respiratory symptoms,  
6:20

smoking and respiratory symptoms in  
children, 6:11-12

smoking characteristics, 5:21, 5:23

smoking habit and neuroticism, 18:8

smoking habit and socioeconomic sta-  
tus, 18:16

smoking habit in the United States,  
5:19-21

smoking in blue- and white-collar  
workers, 7:17

smoking levels and lung pathology,  
6:27

snuff users in the United States,  
13:10

Teenage Self Test scores, 20:22

tobacco chewers in the United  
States, 13:10

## SIBLING SMOKING

adolescents, 17:14

maintenance of smoking and, 18:15

## Sidestream smoke

See SMOKE, CIGARETTE SIDE-  
STREAM; SMOKE STREAMS

## SLEEP

deprived vs. nondeprived smokers,  
15:11

## SMALL AIRWAYS FUNCTION

(See also RESPIRATORY FUNC-  
TION TESTS)

chronic obstructive lung disease and,  
6:11

effect of smoking levels, 6:13-19

pathological lesions of small airways  
and, 6:18-19

screening methods for individuals at  
high risk for chronic obstructive  
lung disease, 6:12

in smokers vs. nonsmokers, 6:13

in smokers vs. nonsmokers vs. ex-  
smokers, 6:14-16

## SMOKE, CIGAR

(See also SMOKERS, CIGAR;  
SMOKING, CIGAR; TOBACCO, CI-  
GAR)

ammonia content, 14:39

aromatic hydrocarbon content, 13:11-  
12

carbon monoxide content, 13:12,  
14:38, 14:104

chemical analysis, 13:11-13

ciliotoxicity, 13:36-37

- effect of inhalation on respiratory tract, 13:15-16
- pH, 13:15-16
- phenol content, 13:12
- SMOKE, CIGARETTE**
- (*See also* **SMOKERS; SMOKING; TOBACCO, CIGARETTE**)
- alcohol content, 14:42
- alkene content, 14:48
- aldehyde content, 14:41
- amine content, 14:41
- aromatic hydrocarbon content, 14:41-42
- benzene compound content, 14:49
- carcinogenic PAH activity, 14:54
- chemical composition percent distribution, 14:35
- constituents, and biological response, 14:26
- constituents, research recommendations, 14:120
- effect of cigarette manufacturing on constituents, 14:28-30
- effect of constituents on enzyme activity, 12:7
- effect of static burning temperature, 14:36
- effect on antibody response in mice, 12:59
- effect on central nervous system, 15:11
- effect on immunoglobulins, 6:31-32
- effect on lung function, 14:90
- effect on macrophages, 6:29-30
- effect on mucociliary system, 6:32-33
- effect on phagocytic activity of alveolar macrophages, 10:17
- effect on phenacetin pharmacokinetics in rats, 12:28-29
- effect on prostaglandin F-2a metabolism in lungs in rabbits, 12:39
- effect on systemic humoral immunity in mice, 10:18
- free fatty acid levels, 14:55
- heterocyclic compounds, 14:52, 14:57
- hydrazine levels, 14:41
- ketone levels, 14:42
- naphthalene levels, 14:51
- nickel levels, 14:59
- nicotine levels, effect on blood pressure, 14:87
- nicotine metabolites, 14:93-94
- nitrile levels, 14:40
- nitrogen compound levels, 14:41
- nitrosamine precursors, 14:41
- nonvolatile nitrosamine levels, 14:45
- pharmacology, 14:85, 15:5
- phenol levels, 14:57
- physical and chemical nature, 14:35
- polynuclear aromatic hydrocarbon indicators, 14:111
- polynuclear aromatic hydrocarbons, 14:51
- radioelements, 14:60
- reaction mechanisms, 14:9
- reduction of toxicity, 14:104, 14:108
- relative molar potency of alkaloids, 14:96
- retention in buccal cavity and respiratory tract, 12:7
- standard smoking conditions for analysis, 14:35
- structural formulae of pesticide residues, 14:62
- sulfur compounds levels, 14:40
- summary of gas and particulate phase constituents, 1:29-30
- summary of toxic and carcinogenic constituents, 1:30
- toxicity reduction methods, 14:114
- weakly acidic heterocyclic compounds structural formulae, 14:56
- SMOKE, CIGARETTE MAINSTREAM**
- (*See also* **SMOKE STREAMS**)
- alkane content, 14:48
- amine content, 14:47
- ammonia content, 14:39
- arsenic content, 14:59
- cadmium content, 14:60
- catechol content, 14:53
- chemical composition, 14:35
- ciliotoxicity and, 14:105
- cyanide content, 14:39-40
- humectant content, 14:63
- nicotine content, 14:45
- nitrogen oxide content, 14:39
- phenol content, effect of filters, 14:106
- tar content determination, 14:43
- temperature profile, 14:36
- SMOKE, CIGARETTE SIDESTREAM**
- (*See also* **SMOKE STREAMS**)
- alkane content, 14:48
- amine content, 14:39, 14:41, 14:47
- catechol content, 14:54
- chemical composition, 14:38

nicotine content, 14:45  
tar content, 14:44  
temperature profile, 14:36

#### **Smoke exposure**

*See* **SMOKE INHALATION**

#### **SMOKE CONDENSATES**

(*See also* **SMOKE, TOBACCO; TARS, TOBACCO**)

benzo(a)pyrene content, 14:112  
carcinogenicity, 13:30-32  
carcinogenicity of experimental cigarettes in mice, 14:30  
cigar, alkaloid content, 13:11  
cigar, aromatic hydrocarbon content, 13:11-12  
cigar, nicotine content, 13:12  
cigar, phenol content, 13:11-12  
effect of cigarette manufacturing on composition, 14:28-30  
effect on antiprotease activity in vitro, 6:28  
effect on elastase release from lungs in rats, 6:29  
effect on enzyme release from polymorphonuclear leukocytes, 6:28  
phenol content, 14:52  
role of cigarette manufacturers in control of constituents, 14:9

#### **SMOKE INHALATION**

(*See also* **SMOKING**)

effect of cigar and pipe smoke pH, 13:15-16  
effect of switching tobacco products on patterns, 13:18-19  
effect on arterioles in dogs, 4:18  
effect on blood pressure in cats, 14:77  
effect on carboxyhemoglobin levels in cigar and pipe smokers, 13:18  
effect on cigarette smoke retention in buccal cavity, 12:7  
effect on coronary heart disease mortality ratios, 4:37  
effect on enzymes in dogs, 14:78  
effect on exercise tolerance in rats, 14:77  
effect on hemodynamics in dogs, 14:76  
effect on leukocyte count, 8:82  
effect on lung neoplasm mortality ratio, 5:14-15  
effect on lung neoplasm mortality ratio in women, 5:21-22

effect on lungs in dogs, 14:76  
effect on lungs in monkeys, 14:76  
effect on mortality, 2:20-21  
effect on mortality in cigar and pipe smokers, 13:18  
effect on mortality ratio, 2:22-24  
effect on mortality ratio in women, 2:26-27  
effect on myocardial infarct morbidity and mortality, 4:35  
effect on nicotine absorption in cigar smokers, 13:16-17  
effect on pregnant rats, 8:10-11  
effect on respiratory system in cigar and pipe smokers, 13:15-16  
effect on tolerance in dogs, 15:16  
exercise in dogs and, 14:78  
exposure methodology, 14:73-74  
in laryngeal neoplasm induction in hamsters, 5:34  
males vs. females, 5:21, 5:23  
maternal, effect on mother and fetus in sheep, 8:53  
maternal, effect on offspring in rats, 8:10-11  
in myocardial infarct induction in dogs, 14:77  
patterns in cigar vs. cigarette vs. pipe smokers in Great Britain, 13:18-19  
patterns in the United States, 2:33

#### **SMOKE, PIPE**

(*See also* **SMOKERS, PIPE; SMOKING, PIPE; TOBACCO, PIPE**)

aromatic hydrocarbon content, 13:11-12

pH, 13:15-16

#### **SMOKE STREAMS**

(*See also* **SMOKE, CIGARETTE MAINSTREAM; SMOKE, CIGARETTE SIDESTREAM**)

carbon monoxide content, 11:15  
involuntary smoking and, 11:5  
ratio of constituents in main- vs. sidestream smoke, 11:6

#### **SMOKE WATCHERS**

cessation program, 21:16

#### **SMOKENDERS**

cessation program, 21:16  
followup evaluation, 19:11

## **SMOKE, TOBACCO**

( *See also* **SMOKE, CIGAR;  
SMOKE, CIGARETTE; SMOKE,  
PIPE; SMOKING**)

absorption of constituents by non-smokers, 11:6, 11:15  
in allergy etiology, 10:23-24  
amine and nitrosamine content, 12:74  
amine content, 14:47  
antigens, identification of, 10:11  
carcinogens, ciliotoxic agents and tumor promoters in gas phase, 5:54-55  
carcinogens, cocarcinogens and tumor promoters in particulate phase, 5:54-57  
constituents, correlation with tobacco leaf characteristics, 14:24  
effect of exposure in allergic children and adults, 10:14, 10:21  
effect of leaf components, 14:11  
effect on alveolar macrophages, 6:30-31, 10:15-16  
effect on blood lipid levels in animals, 4:61  
effect on cardiovascular system in animals with myocardial infarct, 4:45  
effect on cellular and humoral immunity, 6:30-31  
effect on ciliary function, 10:14-15  
effect on enzyme activity, 12:27-28, 12:75-76  
effect on enzyme systems, 10:16  
effect on fetal weight and birth weight in animals, 8:52  
effect on fetal weight and maternal food intake in rats, 8:52-53  
effect on fetus, research needs, 8:79  
effect on immune system, 10:5, 10:17  
effect on lymphocytes in mice, 10:19  
effect on metabolism of food constituents and additives, 12:75-76  
effect on nonsmokers, 11:25  
effect on pre-existing allergies, 10:13  
effect on pregnant animals, 8:52  
effect on rat fetus, 8:53  
effect on tracheobronchial clearance in dogs, 10:15  
eye irritation and, 10:21  
heterocyclic compound carcinogens structural formulae, 14:55

measurement of constituents in enclosed spaces, 11:7-14  
measurement of constituents under natural conditions, 11:16-20  
metal levels, 14:58-59  
in neoplasm induction in animals, 1:17  
nickel levels, 14:59  
pesticide residues, 12:75  
radioelement levels, 14:60  
skin test reactions, 10:13

## **SMOKERS**

(*See also* **SMOKERS, CIGAR;  
SMOKERS, PIPE**)

B and T cell count and ratio, 10:19  
granular leukocyte levels, 10:20

## **SMOKERS, CIGAR**

(*See also* **SMOKE, CIGAR; SMOKING, CIGAR; TOBACCO, CIGAR**)

blood cholesterol levels, 4:61  
bronchitis and emphysema mortality, 13:34  
cardiovascular disease mortality ratio, 13:33  
chronic obstructive pulmonary disease mortality ratio, 13:35  
coronary heart disease mortality ratio, 4:22-23  
effect of inhalation on mortality, 13:18  
esophageal neoplasm mortality, 13:24-25  
esophageal neoplasm mortality ratio, 5:43  
inhalation patterns in Great Britain, 13:18  
leukocyte count, 12:81  
lung neoplasm mortality rates, 5:23  
lung neoplasm mortality ratio, 13:26-28  
mortality, 13:13-14  
myocardial infarct morbidity and mortality, 4:35  
oral neoplasm mortality ratio, 13:21  
relative risk ratio for lip neoplasms, 13:22  
relative risk ratio for lung neoplasms, 13:29-30  
respiratory symptoms, 13:34  
thrombosis mortality rates, 4:59  
in the United States, 13:9

## **SMOKERS, PIPE**

(See also **SMOKE, PIPE; SMOKING, PIPE; TOBACCO, PIPE**)

- blood cholesterol levels, 4:61
- bronchitis and emphysema mortality, 13:34
- cardiovascular disease mortality ratio, 13:33
- chronic obstructive pulmonary disease mortality ratio, 13:35
- coronary heart disease mortality ratio, 4:22-23
- effect of inhalation on mortality, 13:18
- effect of inhalation on respiratory tract, 13:15-16
- esophageal neoplasm mortality, 13:24-25
- esophageal neoplasm mortality ratio, 5:43
- inhalation patterns in Great Britain, 13:18
- leukocyte count, 12:81
- lung neoplasm mortality rates, 5:23
- lung neoplasm mortality ratio, 13:26-28
- mortality, 13:13-14
- myocardial infarct morbidity and mortality, 4:35
- oral neoplasm mortality ratio, 13:21
- relative risk ratio for lip neoplasms, 13:22
- relative risk ratio for lung neoplasms, 13:29-30
- respiratory symptoms, 13:34
- thrombosis mortality rates, 4:59
- in the United States, 13:9

## **SMOKERS VS. NONSMOKERS**

(See also **NONSMOKERS**)

- abruptio placentae, placenta previa, and bleeding during pregnancy, 8:39
- absenteeism, 3:8, 3:10, 3:13
- accidental hemorrhage in pregnancy, 8:39
- activity limitation, 3:13-14
- acute conditions, 3:6
- air pollution and chronic obstructive lung disease, 6:36
- air pollution and lung pathology, 6:36
- alcohol consumption and drug use, 12:41

- alpha-1-antitrypsin deficiency and emphysema, 6:34
- alveolar macrophage migration, 6:31
- angina pectoris morbidity ratios, 4:48
- annual probability of dying, 2:30-34
- antibody response to viral vaccines, 12:58-59
- antipyrine pharmacokinetics, 12:29-31
- anxiety levels, 16:7-8
- Arthus skin test characteristics, 10:10
- asphyxia in infants of, 8:69
- atherosclerosis, 4:10-12, 4:14-16
- B and T lymphocytes, 6:31
- bed disability, 3:12
- bicarbonate levels in infants of, 8:69
- bilirubin levels, 12:34
- birth weight of infants of, 8:11, 8:14-17, 8:20-21
- bladder neoplasm mortality ratio, 5:45-46
- blood calcium levels, 12:84
- blood cholesterol levels, 4:61-62
- blood circulation, 15:12-13
- blood coagulation, 12:84-85
- blood glucose levels, 12:84
- blood lipid levels, 12:83-84
- blood pressure, 4:57
- blood protein levels, 12:84
- breast feeding, 8:48
- bronchitis in gold miners, 7:15
- bronchitis prevalence by occupations, 6:39
- carboxyhemoglobin levels and carbon monoxide occupational exposure, 7:8
- carboxyhemoglobin levels in infants of, 8:69
- carcinoembryonic antigen levels, 12:61-62, 12:86
- cardiovascular disease mortality ratios in Japan, 4:21, 4:34-35
- cerebrovascular disease mortality rates and ratios in males vs. females, 4:51
- chronic obstructive lung disease and mortality, 6:9-10
- ciliary function, 10:15
- clinical effects of propoxyphene, 12:36-37
- clinical effects of selected drugs, 12:36-37
- coronary heart disease morbidity ratios, 4:27-33, 4:36-37

coronary heart disease mortality ratios, 4:22-26, 4:36-37  
definition, 23:24  
drug use patterns, 18:13-15  
duration of gestation, 8:18  
effect of behavior and personality on pharmacokinetics, 12:40-41  
elastase release from macrophages, 6:30  
emphysema, 6:25-26  
emphysema and lung pathology, 6:23-24  
erythrocyte parameters, 12:82-83  
esophageal neoplasm mortality ratio, 5:42-43  
ethanol pharmacokinetics, 12:39  
etiology of fetal and neonatal death, 8:38  
etiology of perinatal death, 8:36  
etiology of stillbirth, 8:37  
fibrosis in asbestos workers, 7:12  
gastric secretion in, 9:13  
gestational age and infant mortality, 8:43, 8:45  
gestational age and risk for abruptio placentae, placenta previa and premature membrane rupture, 8:44, 8:46  
gestational age and risk for preterm delivery, 8:44  
gestational age at birth of infants of, 8:43  
glutethimide pharmacokinetics, 12:33  
growth and development of children of, 8:21-23  
heart conditions, 3:16-17, 3:19  
head circumference in infants of, 8:20-21  
hematocrit in infants of, 8:69  
high density lipoprotein levels in males vs. females, 4:61-62  
histologic changes in esophagus, 5:44  
hospitalization, 3:14-16  
hyaline thickening in small arteries and arterioles in myocardium, 4:16  
hypertension, 4:57  
immunoglobulin containing cell counts in lobar bronchi, 10:17  
immunoglobulin levels, 6:31-32  
infant mortality, 8:27, 8:34  
infant mortality risk, 8:31  
infarct mortality risk in black vs. white mothers, 8:30  
job accident rates, 7:15  
kidney, liver, and lung weights, 12:9  
kidney neoplasm mortality and risk ratios, 5:48-49  
lactation, 8:48  
laryngeal neoplasm mortality ratio, 5:32-33  
learning, 15:19  
leukocyte count, 2:79-82  
level of well-being, 3:18  
long-term study of children of, 8:22-23  
lung diseases in rubber workers, 7:13  
lung function, 6:21  
lung function after cadmium exposure, 7:15  
lung function in black vs. white vs. oriental men and women, 6:21  
lung function in chlorine workers, 7:10  
lung function in cotton workers, 7:9  
lung function in miners, 7:9  
lung neoplasm mortality and asbestos exposure, 7:11  
lung neoplasm mortality in twins, 5:23  
lung neoplasm mortality ratio in males vs. females, 5:11-12  
lung neoplasm mortality ratio in women, 5:20-22  
lung neoplasm risk in asbestos factory workers, 7:11-12  
lung neoplasm risk in insulation workers, 7:11  
lung neoplasms in chloromethyl ether workers, 7:16  
lung neoplasms in uranium miners, 7:14  
lung pathology, 6:24-27  
lung pathology in sudden death victims, 6:18  
macrophage count and ultrastructure, 10:16  
macrophages in bronchopulmonary lavage fluid, 6:29  
maternal weight gain and fetal growth, 8:24-25  
meperidine clearance, 12:39  
mortality in twins, 2:42  
mortality rates, 2:15  
myocardial infarct in women, 12:52

myocardial infarct morbidity and mortality, 4:35-36

neonatal mortality, 8:40

nicotine and cotinine content in urine, 11:24

nicotine content in plasma, 11:24

nicotine content of breast milk in lactating mothers, 8:51

nicotine content of saliva, 15:30

nicotine levels in urine, 15:29

nicotine metabolism, 15:16, 15:9

nitric oxide levels, 14:80

nortriptyline pharmacokinetics, 12:39

obstructive airway diseases in miners, 7:9

oral neoplasm mortality ratio, 5:39-40

osteoporosis, 12:67

pancreatic neoplasm mortality and risk ratios, 5:50-52

pentazocine dosage requirements, 12:36

peptic ulcer healing, 9:9-10

peptic ulcer incidence, 9:5-6

peptic ulcer mortality rates, 9:11

peptic ulcer prevalence, 6:7-8

peptic ulcer prevalence ratios in six countries, 9:8

peptic ulcer size and recurrence, 9:9

perception of health status, 3:14-15

perinatal mortality, 8:35, 8:40

perinatal mortality and maternal age, parity, and education, 8:33

perinatal mortality risk for infants of, 8:32

peripheral vascular disease in diabetics, 4:53

personality, 18:5-10

phagocytic activity of alveolar macrophages, 10:17

phenacetin pharmacokinetics, 12:28-29

phenytoin pharmacokinetics, 12:38

physician visits, 3:14, 3:17

placental changes, 8:69

placental ratios, 8:18

polonium-210 levels in tissues, 10:60-61

preeclampsia and toxemia in pregnancy, 8:42

pregnancy weight gain and fetal growth, 8:24

premature membrane rupture during pregnancy, 8:39

preterm delivery and infant mortality risk, 8:42

prevalence of acute conditions, 3:9

prevalence of chronic conditions, 3:7

prognosis following vascular grafting, 4:53

protease activity of macrophages, 6:29

proteinuria after cadmium exposure, 7:15

rate of decline of FEV and respiratory symptoms, 6:22

respiratory symptoms in twins, 6:35

respiratory tract diseases in young adults, 6:12

respiratory tract infections, 6:20

respiratory tract neoplasms in uranium miners, 7:14

respiratory tract symptoms, 6:20

response to diagnostic tests, 12:79

risk of low birth weight in infants of, 8:13

serum albumin, uric acid, and creatinine concentration, 12:40, 12:84

serum precipitins in, 10:11

skin test reactions to tobacco leaf extracts, 10:13

small airways function, 6:13-16

socioeconomic status and chronic obstructive lung diseases, 6:38

spontaneous abortion, 8:30-32

stillbirth incidence, 8:36

sudden cardiac death, 4:43-44

sudden infant death syndrome in infants, 8:45

T cell counts, 10:19

theophylline pharmacokinetics, 12:31-32

thiocyanate levels in saliva, 15:30

thiocyanates in plasma, 7:7

thiocyanates in urine, 7:7

thrombosis mortality rates, 4:59

tolerance to cigarette smoke, 15:16-17

trace metal levels, 12:73-74

tryptophan metabolism, 12:67

umbilical artery changes, 8:69

vitamin B<sub>12</sub> levels in pregnancy, 8:73

vitamin C levels in breast milk of lactating mothers, 8:52

vitamin C levels in pregnancy, 8:74

vitamin C levels in serum, 12:34

warfarin metabolism, 12:55